-
Evacetrapib (LY2484595) in Cell Assays
2026-09-19
A practical, evidence-based guide to using Evacetrapib (LY2484595), SKU A4377, in cell viability, proliferation, and cytotoxicity workflows. It combines assay controls, ferroptosis-aware interpretation, protocol starting points, and supplier-selection guidance without overstating product-specific validation.
-
ECL Chemiluminescent Substrate Detection Kit Guide
2026-09-19
Learn how to use an ECL Chemiluminescent Substrate Detection Kit to validate omics-derived protein targets, troubleshoot weak or noisy Western blot signals, and extend HRP detection to immunoassay and membrane-based nucleic acid workflows. Practical starting parameters, comparative guidance, and limitations help convert mechanistic findings into reproducible chemiluminescent readouts.
-
GW 4869 for Exosome Osteogenesis Studies
2026-09-18
Use GW 4869 to separate lithium-driven exosome secretion from direct effects on bone mesenchymal stem cells. This workflow connects neutral sphingomyelinase inhibition with Wnt10a cargo analysis, β-catenin signaling, and functional osteogenesis assays.
-
Annexin V-Cy5 Apoptosis Kit Workflow
2026-09-18
The Annexin V-Cy5 Apoptosis Kit provides a fast phosphatidylserine-based readout for separating apoptosis from non-apoptotic lysosomal stress. This workflow translates a reversible zebrafish microglial model into practical fluorescence microscopy and flow cytometry apoptosis detection strategies.
-
Q-VD(OMe)-OPh in Apoptosis Assay Workflows
2026-09-17
Q-VD(OMe)-OPh gives researchers a practical way to separate caspase-dependent apoptosis from ferroptosis, autophagy, and other death phenotypes. This workflow-focused guide explains assay setup, controls, troubleshooting, and translational applications from colorectal cancer resistance studies to neuroprotection research.
-
Bifendate–Cyclosporine Interaction by CYP3A4 Genotype
2026-09-17
The reference study shows that Bifendate decreases cyclosporine exposure and increases oral clearance, with the largest effect in healthy subjects carrying CYP3A4*18B/*18B. Its key contribution is a genotype-stratified, randomized crossover assessment that connects a clinically relevant drug interaction to pharmacogenetic variation.
-
Carvedilol: Translational Frontiers in β-Blockade
2026-09-16
Carvedilol offers more than cardiovascular pharmacology: its nonselective β-adrenergic blockade, α1 antagonism, antioxidant activity, and vascular effects create a versatile translational research platform. New hematopoietic transplantation evidence shows why receptor selectivity and tissue context must guide experimental design.
-
(-)-Blebbistatin: Reliable Cytoskeletal Assays
2026-09-15
Learn how (-)-Blebbistatin (SKU B1387) can help distinguish actomyosin-dependent changes from nonspecific toxicity in viability, proliferation, and mechanobiology workflows. This scenario-driven guide covers mechanism, dosing, controls, interpretation, and practical vendor-selection criteria.
-
SIRT4–GDH Axis in Liver Fibrosis
2026-09-15
The reference study identifies a metabolic mechanism in which reduced SIRT4 activity permits GDH-dependent glutamine catabolism in hepatic stellate cells, supporting α-ketoglutarate production, proliferation, and fibrotic progression. Pharmacological GDH inhibition and SIRT4 overexpression each produced antifibrotic effects in cellular and animal experiments, positioning glutamine metabolism as a potential therapeutic target.
-
Spirocyclic POM Analogues Target MmpL3 in TB
2026-09-14
This 2024 Bioorganic Chemistry study develops spirocyclic phenyl oxazole methyl derivatives as MmpL3-directed anti-tuberculosis candidates. Compound 5c combined submicromolar activity against Mycobacterium tuberculosis with activity against drug-resistant clinical isolates, acceptable preliminary ADME and pharmacokinetic properties, and low cytotoxicity in THP-1 cells.
-
PHF2, Neuroinflammation, and Alzheimer’s Disease
2026-09-14
A 2025 Molecular Psychiatry study identifies the histone demethylase PHF2 as an upstream regulator of inflammatory gene expression in Alzheimer’s disease. Using human tissue, patient-derived neurons, ChIP-seq, genetic perturbation, and a 5xFAD mouse model, the authors connect PHF2 reduction with lower glial activation, improved synaptic function, and better spatial memory.
-
BMS-777607 for MET Signaling and Platelet Research
2026-09-13
BMS-777607 supports controlled MET-family pathway perturbation in cancer metastasis models and exploratory hiPSC-derived megakaryocyte studies. This guide connects phospho-MET assays, platelet differentiation workflows, dose handling, and troubleshooting without overstating evidence from either research domain.
-
Nonselective β-Blockade and HCT Engraftment
2026-09-12
This study shows that nonselective β-adrenergic receptor inhibition can impair hematopoietic regeneration after transplantation, whereas β1-selective inhibition has a substantially different effect. Mouse experiments and human cohort analyses connect the finding to allogeneic transplantation, posttransplant chemotherapy, platelet engraftment, survival, and hematopoietic cell dose.
-
RNA Clean and Concentrator Kit for IVT RNA
2026-09-12
Build a cleaner path from enzymatic RNA synthesis to LNP formulation, RT-qPCR, and cell-based assays with a rapid membrane workflow. This guide shows how the RNA Clean and Concentrator Kit supports high-throughput cleanup while addressing size selection, salt carryover, low yield, and translation-readiness.
-
EdU Flow Cytometry Assay Kits (Cy5): Practical Guide
2026-09-11
Learn how to use EdU Flow Cytometry Assay Kits (Cy5) for direct S-phase DNA synthesis measurement in tumor, immune, and drug-response models. This workflow combines click chemistry specificity, far-red Cy5 detection, and multiplex-compatible sample handling to improve proliferation data quality.